This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Phibro Animal (PAHC) Q1 Earnings Lag Estimates, Sales Up Y/Y
by Zacks Equity Research
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
OPKO Health (OPK) Incurs Loss in Q3, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE in Q3; adjusted gross margin remains pressed.
Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
athenahealth (ATHN) Q3 Earnings Beat, Bookings Down Y/Y
by Zacks Equity Research
athenahealth's (ATHN) Business and Services unit sees a strong Q3; 2018 guidance maintained.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.
Can Canadian Market Drive Canopy Growth (CGC) Q2 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.
BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
Wright Medical (WMGI) Reports Q3 Loss, Raises '18 Guidance
by Zacks Equity Research
Growth in the upper and the lower extremity segments drives Wright Medical's (WMGI) Q3 results
Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.
Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.
Hologic (HOLX) Q4 Earnings Miss, Revenues Top Estimates
by Zacks Equity Research
Tough year-over-year comparisons and soft Diagnostics sales hurt Hologic's (HOLX) performance in Q4.
Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performance by GeneSight, EndoPredict, and Prolaris tests in Q1.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q1
by Nabaparna Bhattacharya
Cardinal Health (CAH) Q1 results benefit from strong sales in the Pharmaceutical and the Medical segments.
STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q2.
Luminex's (LMNX) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Luminex (LMNX) gains from segmental contributions in Q3; margins contract.
CVS Health's (CVS) Q3 Earnings Top Estimate, Gross Margin Up
by Zacks Equity Research
CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.
Becton, Dickinson (BDX) Q4 Earnings Beat, FY19 View Strong
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4; fiscal 2019 guidance solid.
AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4.
Henry Schein's (HSIC) Q3 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recording year-over-year growth in Q3 encourages us.
PRA Health's (PRAH) Q3 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) posts year-over-year double-digit growth in earnings, revenues and net new business in Q3. However, increasing labor-related costs in the Clinical Research wing are a concern.
CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3
by Zacks Equity Research
Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.
Hill-Rom (HRC) Q4 Earnings Top Estimates on All-Line Growth
by Zacks Equity Research
Hill-Rom (HRC) benefits from a robust year-over-year revenue increase on solid domestic growth in Q4, driven by a strong segmental performance at both Patient Support Systems and Front Line Care.
Integer Holdings (ITGR) Beats on Q3 Earnings and Revenues
by Zacks Equity Research
Integer Holdings (ITGR) gains from solid Medical sales contribution in Q3; 2018 guidance solid.